Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Argenx participates in a conference call with Cowen » 10:25
03/30/21
03/30
10:25
03/30/21
10:25
ARGX

Argenx

$271.79 /

+0.59 (+0.22%)

Biotechnology Analyst…

Biotechnology Analyst Werber holds a conference call with management on March 30 at 11 am hosted by Cowen.

ShowHide Related Items >><<
ARGX Argenx
$271.79 /

+0.59 (+0.22%)

ARGX Argenx
$271.79 /

+0.59 (+0.22%)

03/05/21 H.C. Wainwright
Argenx price target raised to $320 from $265 at H.C. Wainwright
02/18/21 Cowen
Argenx price target raised to $430 from $317 at Cowen
02/10/21 Barclays
Argenx price target raised to EUR 295 from EUR 215 at Barclays
02/04/21 Piper Sandler
Argenx price target raised to $309 from $303 at Piper Sandler
  • 03
    Feb
  • 28
    May
ARGX Argenx
$271.79 /

+0.59 (+0.22%)

Conference/Events
Argenx participates in a conference call with Cowen » 04:55
03/30/21
03/30
04:55
03/30/21
04:55
ARGX

Argenx

$271.34 /

-11.17 (-3.95%)

Biotechnology Analyst…

Biotechnology Analyst Werber holds a conference call with management on March 30 at 11 am hosted by Cowen.

ShowHide Related Items >><<
ARGX Argenx
$271.34 /

-11.17 (-3.95%)

ARGX Argenx
$271.34 /

-11.17 (-3.95%)

03/05/21 H.C. Wainwright
Argenx price target raised to $320 from $265 at H.C. Wainwright
02/18/21 Cowen
Argenx price target raised to $430 from $317 at Cowen
02/10/21 Barclays
Argenx price target raised to EUR 295 from EUR 215 at Barclays
02/04/21 Piper Sandler
Argenx price target raised to $309 from $303 at Piper Sandler
  • 03
    Feb
  • 28
    May
ARGX Argenx
$271.34 /

-11.17 (-3.95%)

Hot Stocks
Hansa Biopharma announces preclinical research collaboration with Argenx » 14:13
03/29/21
03/29
14:13
03/29/21
14:13
ARGX

Argenx

$271.53 /

-10.98 (-3.89%)

Hansa Biopharma AB…

Hansa Biopharma AB announced that they have entered into a preclinical research collaboration agreement with Argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. "The preclinical research collaboration is set up to explore the potential of combining imlifidase, Hansa's IgG antibody-cleaving enzyme, and efgartigimod, argenx's FcRn antagonist, which are both in development for indications known to be driven by disease-causing IgGs. A combination of imlifidase and efgartigimod could potentially be used in both the acute and chronic setting of autoimmune diseases and transplantation. Under the preclinical research collaboration agreement, both parties will contribute equally in terms of resource allocation and will share all intellectual property and data developed through the collaboration. Both parties will maintain exclusive rights to their respective technologies and products," Hansa stated.

ShowHide Related Items >><<
ARGX Argenx
$271.53 /

-10.98 (-3.89%)

ARGX Argenx
$271.53 /

-10.98 (-3.89%)

03/05/21 H.C. Wainwright
Argenx price target raised to $320 from $265 at H.C. Wainwright
02/18/21 Cowen
Argenx price target raised to $430 from $317 at Cowen
02/10/21 Barclays
Argenx price target raised to EUR 295 from EUR 215 at Barclays
02/04/21 Piper Sandler
Argenx price target raised to $309 from $303 at Piper Sandler
  • 03
    Feb
  • 28
    May
ARGX Argenx
$271.53 /

-10.98 (-3.89%)

Conference/Events
Argenx participates in a conference call with Cowen » 16:15
03/25/21
03/25
16:15
03/25/21
16:15
ARGX

Argenx

$293.52 /

+10.4 (+3.67%)

Biotechnology Analyst…

Biotechnology Analyst Werber holds a conference call with management on March 30 at 11 am hosted by Cowen.

ShowHide Related Items >><<
ARGX Argenx
$293.52 /

+10.4 (+3.67%)

ARGX Argenx
$293.52 /

+10.4 (+3.67%)

03/05/21 H.C. Wainwright
Argenx price target raised to $320 from $265 at H.C. Wainwright
02/18/21 Cowen
Argenx price target raised to $430 from $317 at Cowen
02/10/21 Barclays
Argenx price target raised to EUR 295 from EUR 215 at Barclays
02/04/21 Piper Sandler
Argenx price target raised to $309 from $303 at Piper Sandler
  • 03
    Feb
  • 28
    May
ARGX Argenx
$293.52 /

+10.4 (+3.67%)

Over a month ago
Recommendations
Argenx price target raised to $320 from $265 at H.C. Wainwright » 06:12
03/05/21
03/05
06:12
03/05/21
06:12
ARGX

Argenx

$290.57 /

-25.65 (-8.11%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Argenx to $320 from $265 and reiterates a Neutral rating on the shares. Argenx on the earnings call laid out its plans for the commercialization of efgartigimod in myasthenia gravis, Tsao tells investors in a research note.

ShowHide Related Items >><<
ARGX Argenx
$290.57 /

-25.65 (-8.11%)

ARGX Argenx
$290.57 /

-25.65 (-8.11%)

02/18/21 Cowen
Argenx price target raised to $430 from $317 at Cowen
02/10/21 Barclays
Argenx price target raised to EUR 295 from EUR 215 at Barclays
02/04/21 Piper Sandler
Argenx price target raised to $309 from $303 at Piper Sandler
02/03/21 Chardan
Chardan lays out five reasons to buy Immunovant after pause-related pullback
  • 03
    Feb
  • 28
    May
ARGX Argenx
$290.57 /

-25.65 (-8.11%)

Hot Stocks
Argenx announces FDA acceptance of efgartigimod BLA filing » 05:28
03/02/21
03/02
05:28
03/02/21
05:28
ARGX

Argenx

$341.20 /

+10.8 (+3.27%)

Argenx announced that the…

Argenx announced that the FDA has accepted for review the biologics license application, or BLA, for intravenous, or IV, efgartigimod, the company's investigational FcRn antagonist and lead product candidate, for the treatment of generalized myasthenia gravis, or gMG. The FDA has set a standard 10-month review process with a PDUFA target action date of December 17.

ShowHide Related Items >><<
ARGX Argenx
$341.20 /

+10.8 (+3.27%)

ARGX Argenx
$341.20 /

+10.8 (+3.27%)

02/18/21 Cowen
Argenx price target raised to $430 from $317 at Cowen
02/10/21 Barclays
Argenx price target raised to EUR 295 from EUR 215 at Barclays
02/04/21 Piper Sandler
Argenx price target raised to $309 from $303 at Piper Sandler
02/03/21 Chardan
Chardan lays out five reasons to buy Immunovant after pause-related pullback
  • 03
    Feb
  • 28
    May
ARGX Argenx
$341.20 /

+10.8 (+3.27%)

Recommendations
Argenx price target raised to $430 from $317 at Cowen » 07:44
02/18/21
02/18
07:44
02/18/21
07:44
ARGX

Argenx

$369.01 /

-1.75 (-0.47%)

Cowen analyst Yaron…

Cowen analyst Yaron Werber raised the firm's price target on Argenx to $430 from $317 and keeps an Outperform rating on the shares. The price target increase reflects his updated model and improved probability of success following multiple updates over the past year.

ShowHide Related Items >><<
ARGX Argenx
$369.01 /

-1.75 (-0.47%)

ARGX Argenx
$369.01 /

-1.75 (-0.47%)

02/10/21 Barclays
Argenx price target raised to EUR 295 from EUR 215 at Barclays
02/04/21 Piper Sandler
Argenx price target raised to $309 from $303 at Piper Sandler
02/03/21 Chardan
Chardan lays out five reasons to buy Immunovant after pause-related pullback
02/02/21
Fly Intel: Top five analyst downgrades
  • 03
    Feb
  • 28
    May
ARGX Argenx
$369.01 /

-1.75 (-0.47%)

Recommendations
Argenx price target raised to EUR 295 from EUR 215 at Barclays » 14:22
02/10/21
02/10
14:22
02/10/21
14:22
ARGX

Argenx

$374.61 /

-1.02 (-0.27%)

Barclays analyst Emily…

Barclays analyst Emily Field raised the firm's price target on Argenx to EUR 295 from EUR 215 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
ARGX Argenx
$374.61 /

-1.02 (-0.27%)

ARGX Argenx
$374.61 /

-1.02 (-0.27%)

02/04/21 Piper Sandler
Argenx price target raised to $309 from $303 at Piper Sandler
02/03/21 Chardan
Chardan lays out five reasons to buy Immunovant after pause-related pullback
02/02/21
Fly Intel: Top five analyst downgrades
02/02/21 Wells Fargo
Argenx price target raised to $326 from $272 at Wells Fargo
  • 03
    Feb
  • 28
    May
ARGX Argenx
$374.61 /

-1.02 (-0.27%)

Recommendations
Argenx price target raised to $309 from $303 at Piper Sandler » 11:16
02/04/21
02/04
11:16
02/04/21
11:16
ARGX

Argenx

$358.75 /

-2.16 (-0.60%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Argenx to $309 from $303 and keeps a Neutral rating on the shares after the company raised proceeds of $1.15B by issuing 3.59M ADSs, bringing its pro forma cash to about $3.24B to support the U.S. launch expected this year for efgartigimod for generalized Myasthenia Gravis, or gMG. The analyst, who said he is confident in FDA approval, models efgartigimod for gMG sales of $48M in the second half of 2021.

ShowHide Related Items >><<
ARGX Argenx
$358.75 /

-2.16 (-0.60%)

ARGX Argenx
$358.75 /

-2.16 (-0.60%)

02/03/21 Chardan
Chardan lays out five reasons to buy Immunovant after pause-related pullback
02/02/21
Fly Intel: Top five analyst downgrades
02/02/21 Wells Fargo
Argenx price target raised to $326 from $272 at Wells Fargo
02/01/21 Piper Sandler
Argenx downgraded to Neutral from Overweight at Piper Sandler
  • 03
    Feb
  • 28
    May
ARGX Argenx
$358.75 /

-2.16 (-0.60%)

Recommendations
Chardan lays out five reasons to buy Immunovant after pause-related pullback » 12:02
02/03/21
02/03
12:02
02/03/21
12:02
IMVT

Immunovant

$26.27 /

+0.765 (+3.00%)

, ARGX

Argenx

$354.47 /

+30.19 (+9.31%)

Chardan analyst Gbola…

Chardan analyst Gbola Amusa noted that Immunovant (IMVT) shares were down 42% yesterday after the company announced it voluntarily paused dosing patients in two phase 2 trials after elevated LD-C levels were seen in treated patients in the ASCEND GO-2 trial in thyroid eye disease. While Amusa has lowered the firm's price target on Immunovant shares to $55 from $60, the analyst keeps a Buy rating on the stock and lays out five reasons to buy the shares following the news. The result in ASCEND GO-2 may be "roughly consistent with a systematic review of thyroid studies;" the license holder of IMVT-1401 in Greater China did not observe similar increases in cholesterol in non-thyroid indications; Argenx (ARGX) has stated that it is not aware of cholesterol increases in its studies; "big pharma" demand for anti-FcRn assets is likely "still high" after recent deals in the space; and the selloff in the stock are the five reasons highlighted by Amusa.

ShowHide Related Items >><<
IMVT Immunovant
$26.27 /

+0.765 (+3.00%)

ARGX Argenx
$354.47 /

+30.19 (+9.31%)

IMVT Immunovant
$26.27 /

+0.765 (+3.00%)

02/03/21 H.C. Wainwright
Immunovant price target lowered to $33 from $54 at H.C. Wainwright
02/02/21 Credit Suisse
Credit Suisse downgrades Immunovant to Neutral after IMVT-1401 trials pause
02/02/21 Credit Suisse
Immunovant downgraded to Neutral from Outperform at Credit Suisse
02/02/21 Stifel
Stifel cuts Immunovant price target to $33 after pause, sees buying opportunity
ARGX Argenx
$354.47 /

+30.19 (+9.31%)

02/02/21
Fly Intel: Top five analyst downgrades
02/02/21 Wells Fargo
Argenx price target raised to $326 from $272 at Wells Fargo
02/01/21 Piper Sandler
Argenx downgraded to Neutral from Overweight at Piper Sandler
02/01/21 JMP Securities
Argenx price target raised to $421 from $307 at JMP Securities
IMVT Immunovant
$26.27 /

+0.765 (+3.00%)

  • 03
    Feb
  • 02
    Sep
  • 28
    May
  • 14
    Apr
IMVT Immunovant
$26.27 /

+0.765 (+3.00%)

IMVT Immunovant
$26.27 /

+0.765 (+3.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.